Venetoclax
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Venetoclax
- Venetoclax: From Hematologic Malignancy Standard-of-Care to Acute Myeloid Leukemia (Taiwan Repurposing Candidate)
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence (Myeloid Leukemia / AML)
- Literature Evidence (Myeloid Leukemia / AML)
- Other Notable Predicted Indications (Secondary Candidates)
- Taiwan Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Venetoclax: From Hematologic Malignancy Standard-of-Care to Acute Myeloid Leukemia (Taiwan Repurposing Candidate)
One-Sentence Summary
Venetoclax (DB11581) is a selective BCL-2 inhibitor already used internationally across several B-cell and myeloid malignancies, but it is not currently marketed in Taiwan (0 authorizations on file). Among the 10 candidate indications TxGNN surfaced for this drug, Acute Myeloid Leukemia (myeloid leukemia) stands out as the only one backed by a genuinely mature evidence base — 50+ clinical trials and 20 publications, including combination regimens already treated as standard of care internationally — while most of the other 9 candidates are thin, mislabeled, or purely score-driven.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack — venetoclax is not yet marketed in Taiwan, so no locally approved indication text exists |
| Predicted New Indication (headline) | Myeloid Leukemia (Acute Myeloid Leukemia) |
| TxGNN Prediction Score | 99.47% (global model rank 5,697) |
| Evidence Level | L1 |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold (regulatory/safety gate) — see rationale below |
Note on scope: this evidence pack is a multi-indication candidate bundle (TW-DB11581-multi) containing 10 ranked predictions. The single highest-scoring prediction by raw TxGNN rank (a specific pre-germinal-center CLL/SLL subtype) has almost no supporting evidence, so this report leads with the candidate that has the strongest, most decision-relevant evidence instead of the raw #1 score. All 10 are summarized below for completeness.
Overview of All Predicted Indications
| Rank | Disease | TxGNN Score | Evidence Level | Decision Stage | Recommendation |
|---|---|---|---|---|---|
| 1 | Pregerminal center CLL/SLL | 99.55% | L4 | S1 | Research Question |
| 2 | CLL/SLL (IGHV-mutated subtype) | 99.55% | L5 | S0 | Hold |
| 3 | Hodgkin lymphoma ⚠ | 99.51% | L3 | S1 | Research Question |
| 4 | Myeloid leukemia (AML) | 99.47% | L1 | S3 | Proceed with Guardrails |
| 5 | Chronic myelogenous leukemia (CML), BCR-ABL1+ | 99.36% | L2 | S2 | Research Question |
| 6 | Ewing sarcoma | 99.21% | L4 | S0 | Hold |
| 7 | Follicular lymphoma | 99.15% | L2 | S2 | Research Question |
| 8 | Metastatic neoplasm (generic) | 99.14% | L3 | S0 | Hold |
| 9 | Malignant spiradenoma | 99.12% | L5 | S0 | Hold |
| 10 | AML with t(8;21) translocation | 99.08% | L4 | S1 | Research Question |
⚠ Data quality flag (Rank 3, Hodgkin lymphoma): the 50 attached trials and 20 publications are overwhelmingly CLL, DLBCL, mantle cell lymphoma, and follicular lymphoma studies — not one title explicitly references classic Hodgkin lymphoma. This strongly suggests a label/classification mismatch (a broad "B-cell lymphoma" evidence set was attached to the Hodgkin lymphoma node). This indication should not be advanced without manual re-verification of the underlying disease mapping.
Why is This Prediction Reasonable?
The structured original_moa field for this bundle is empty (data gap), and no Taiwan-approved original indication text exists because the drug is not yet marketed locally. However, the mechanism is consistently documented across the evidence pack's own rationale fields: venetoclax is a selective, orally available BCL-2 (B-cell lymphoma-2) inhibitor that restores the intrinsic apoptotic pathway in cells that have become abnormally dependent on BCL-2 for survival.
This mechanism directly explains the strength of the AML signal: leukemic blasts and leukemic stem cells frequently rely on BCL-2-mediated apoptosis evasion, and venetoclax combined with hypomethylating agents (azacitidine/decitabine) or low-dose cytarabine has become a well-established regimen for patients — particularly older or unfit patients — with newly diagnosed or relapsed/refractory AML. Unlike most of the other 9 candidates in this pack, the AML prediction is supported by a deep, multi-decade trial and publication record spanning Phase 1 through Phase 3, including maintenance-therapy and post-transplant settings.
By contrast, several other candidates in this pack (CLL/SLL molecular subtypes, Ewing sarcoma, malignant spiradenoma) share the same underlying BCL-2 rationale in principle, but have no disease-specific trials or only preclinical/mechanistic literature — meaning the mechanistic plausibility is real, but clinical validation is essentially absent.
Clinical Trial Evidence (Myeloid Leukemia / AML)
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06713837 | Phase 3 | Recruiting | 339 | IMPACT-AML: randomized pragmatic trial comparing high- vs low-intensity reinduction therapy in 1st/2nd relapse AML |
| NCT03404193 | Phase 2 | Terminated | 235 | Venetoclax + 10-day decitabine in newly diagnosed elderly or R/R AML and high-risk MDS |
| NCT03941964 | Phase 3 | Completed | 60 | Outpatient venetoclax + azacitidine/decitabine in treatment-naïve AML ineligible for intensive chemotherapy — reflects the regulatory standard-of-care regimen |
| NCT04161885 | Phase 3 | Terminated | 465 | VIALE-T: venetoclax + azacitidine as post-allogeneic transplant maintenance to improve overall survival |
| NCT05404906 | Phase 2/3 | Recruiting | 124 | Azacitidine + venetoclax maintenance in favorable-risk AML after first remission |
| NCT02287233 | Phase 1/2 | Completed | 94 | Foundational study: venetoclax + low-dose cytarabine in treatment-naïve AML patients ≥60 years ineligible for anthracycline induction |
| NCT07007312 | Phase 3 | Recruiting | 1,300 | Ziftomenib added to standard-of-care venetoclax+azacitidine (or intensive 7+3) in NPM1-mutated/KMT2A-rearranged AML |
| NCT07469046 | Phase 3 | Not yet recruiting | 308 | Venetoclax+azacitidine+homoharringtonine vs venetoclax+azacitidine alone in elderly newly diagnosed AML |
| NCT06611839 | Phase 1/2 | Recruiting | 29 | Venetoclax + ivosidenib + azacitidine triple regimen in IDH1-mutated AML |
| NCT04146038 | Phase 2 | Completed | 5 | Salsalate added to venetoclax + decitabine/azacitidine in AML or advanced MDS/MPN |
10 of 50+ available trials shown, prioritized by phase, sample size, and direct relevance to standard-of-care regimens.
Literature Evidence (Myeloid Leukemia / AML)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37925935 | 2023 | Review | Biomedicine & Pharmacotherapy | Overview of venetoclax's antileukemic activity in preclinical AML models and clinical trials, alone and in combination |
| 31203996 | 2019 | Review | Best Practice & Research Clin Haematology | Venetoclax-based therapies contextualized among 8 new AML drugs approved since 2017 |
| 34329576 | 2021 | Phase 2 cohort | The Lancet Haematology | Venetoclax + cladribine/idarubicin/cytarabine (CLIA) in newly diagnosed AML/high-risk MDS, patients ≤65 years |
| 35046058 | 2022 | Cohort | Clinical Cancer Research | Venetoclax + azacitidine efficacy/safety in treatment-naïve IDH1/2-mutant AML |
| 38866760 | 2024 | Review | Cell Death & Disease | Venetoclax therapy and emerging resistance mechanisms in AML |
| 39303729 | 2024 | Phase 2 cohort | The Lancet Haematology | Decitabine + venetoclax + ponatinib in advanced-phase Ph+ myeloid disease and Ph+ AML |
| 37599456 | 2024 | Network meta-analysis | J Chemotherapy | Venetoclax+azacitidine vs ivosidenib/enasidenib in unfit newly diagnosed IDH1/2-mutant AML — favors venetoclax combination on OS |
| 34966123 | 2022 | Review | Current Opinion in Hematology | Survey of venetoclax combination regimens in AML and MDS |
| 32031033 | 2020 | Review | Leukemia & Lymphoma | Venetoclax + HMA/LDAC established as new standard of care for frontline unfit/elderly AML |
| 39246164 | 2024 | Review | Expert Review of Hematology | Relapse and resistance patterns after frontline venetoclax-based AML therapy, and second-line strategies |
Other Notable Predicted Indications (Secondary Candidates)
- CML, BCR-ABL1 positive (Rank 5, L2, Research Question): Multiple Phase 2 trials pair venetoclax with TKIs (dasatinib, ponatinib) to eradicate TKI-persistent leukemic stem cells — an active research line, not yet standard of care (e.g., NCT02689440, NCT04188405).
- Follicular lymphoma (Rank 7, L2, Research Question): Directly aligned with the t(14;18) BCL-2 overexpression that defines FL. A dedicated Phase 2 (venetoclax+obinutuzumab+bendamustine, PrE0403, PMID 40355425) reported in 2025, but efficacy has been inconsistent enough that FL is not yet a registered indication.
- Ranks 1, 2, 6, 8, 9, 10 (Hold / low priority): Either extremely narrow molecular subtypes with no dedicated trials, a generic multi-cancer label ("metastatic neoplasm") that mixes unrelated solid tumors, or (malignant spiradenoma) a rare tumor with zero supporting trials or literature. None should be advanced without new dedicated evidence.
Taiwan Market Information
Venetoclax currently holds 0 marketing authorizations in Taiwan (market status: 未上市 / not marketed). No product licenses, dosage forms, or approved indication text are available in this evidence pack.
Cytotoxicity
Venetoclax is an antineoplastic agent (BCL-2 inhibitor used across CLL/SLL, AML, and other B-cell malignancies), so this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (selective BCL-2 inhibitor) — consistently identified as such across this evidence pack's rationale entries |
| Myelosuppression Risk | Not available in this evidence pack |
| Emetogenicity Classification | Not available in this evidence pack |
| Monitoring Items | Not available in this evidence pack |
| Handling Protection | Not available in this evidence pack |
Myelosuppression risk, emetogenicity, monitoring, and handling-protection details are not available in this evidence pack — please refer to the package insert warnings and precautions once the TFDA label (see Data Gap DG001 below) is obtained.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-drug interaction data are all currently unavailable in this evidence pack — DDI query status: not found.)
Conclusion and Next Steps
Decision: Hold (regulatory/safety gate), with the underlying AML efficacy case otherwise meeting Proceed with Guardrails criteria.
Rationale:
- The myeloid leukemia (AML) indication has strong, mature clinical evidence (L1, 50+ trials, 20 publications) and reflects a therapy already treated as standard of care internationally.
- However, a Blocking-severity data gap (DG001) means TFDA package-insert warnings/contraindications have not yet been obtained, which by this pipeline's own criteria prevents completion of the S1 safety pre-assessment — so no advancement decision can be finalized until that gap is closed, regardless of efficacy strength.
- Venetoclax is not currently marketed in Taiwan (0 authorizations), so there is no local regulatory precedent to lean on; any repurposing pathway would likely require a full new registration route rather than a label-extension route.
To proceed, the following is needed:
- TFDA package insert (warnings, contraindications) — remediation: download and parse from the TFDA website (DG001, Blocking).
- Structured mechanism-of-action confirmation from DrugBank to replace the current data gap (DG002, High).
- Manual re-verification of the Hodgkin lymphoma (Rank 3) evidence set, which appears mismatched to the disease label.
- A formal DDI query, since the current query returned "not_found" rather than a populated result.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.